Literature DB >> 21266785

Short-term prognosis of adaptive servo-ventilation therapy in patients with heart failure.

Takashi Koyama1, Hiroyuki Watanabe, Gen Igarashi, Shigenori Terada, Shin Makabe, Hiroshi Ito.   

Abstract

BACKGROUND: This study tested the hypothesis that adaptive servo-ventilation (ASV) therapy improves the prognosis of heart failure (HF) patients, regardless of the severity of sleep-disordered breathing (SDB). METHODS AND
RESULTS: 88 consecutive patients were divided into 4 groups based on ASV therapy and SDB severity. The incidence of HF, brain natriuretic peptide (BNP) levels, and left ventricular ejection fraction (LVEF) were followed for 12 months. Fewer HF events, together with an increase in LVEF and a decrease in BNP, occurred in ASV-treated patients with both non-to-mild and moderate-to-severe SDB.
CONCLUSIONS: ASV therapy improves the short-term prognosis in HF-patients, regardless SDB severity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21266785     DOI: 10.1253/circj.cj-10-0956

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  11 in total

Review 1.  Phosphinic peptides as zinc metalloproteinase inhibitors.

Authors:  V Dive; D Georgiadis; M Matziari; A Makaritis; F Beau; P Cuniasse; A Yiotakis
Journal:  Cell Mol Life Sci       Date:  2004-08       Impact factor: 9.261

Review 2.  The importance of sleep-disordered breathing in cardiovascular disease.

Authors:  Dominik Linz; Holger Woehrle; Thomas Bitter; Henrik Fox; Martin R Cowie; Michael Böhm; Olaf Oldenburg
Journal:  Clin Res Cardiol       Date:  2015-04-23       Impact factor: 5.460

3.  Sleep-disordered Breathing in Heart Failure - Current State of the Art.

Authors:  Martin R Cowie; Holger Woehrle; Olaf Oldenburg; Thibaud Damy; Peter van der Meer; Erland Erdman; Marco Metra; Faiez Zannad; Jean-Noel Trochu; Lars Gullestad; Michael Fu; Michael Böhm; Angelo Auricchio; Patrick Levy
Journal:  Card Fail Rev       Date:  2015-04

Review 4.  Positive airway pressure therapy for heart failure.

Authors:  Takao Kato; Shoko Suda; Takatoshi Kasai
Journal:  World J Cardiol       Date:  2014-11-26

Review 5.  Use of adaptive servo ventilation therapy as treatment of sleep-disordered breathing and heart failure: a systematic review and meta-analysis.

Authors:  Adrian V Hernandez; Anne Jeon; Jack Denegri-Galvan; Fernando Ortega-Loayza; Monica Felix-Moscoso; Vinay Pasupuleti; Roop Kaw
Journal:  Sleep Breath       Date:  2019-07-03       Impact factor: 2.816

6.  Performance of conventional and enhanced adaptive servoventilation (ASV) in heart failure patients with central sleep apnea who have adapted to conventional ASV.

Authors:  Olaf Oldenburg; Jens Spießhöfer; Henrik Fox; Natalie Prib; Dieter Horstkotte
Journal:  Sleep Breath       Date:  2014-11-21       Impact factor: 2.816

Review 7.  [Sleep-related breathing disorders and (resulting) cardiovascular diseases].

Authors:  O Oldenburg; T Bitter; H Fox; D Horstkotte
Journal:  Herz       Date:  2014-02       Impact factor: 1.443

8.  Effects of adaptive servo-ventilation therapy on cardiac function and remodeling in patients with chronic heart failure (SAVIOR-C): study protocol for a randomized controlled trial.

Authors:  Yoshihiko Seino; Shin-Ichi Momomura; Yasuki Kihara; Hitoshi Adachi; Yoshio Yasumura; Hiroyuki Yokoyama
Journal:  Trials       Date:  2015-01-16       Impact factor: 2.279

9.  Positive airway pressure therapy for the treatment of central sleep apnoea associated with heart failure.

Authors:  Shuhei Yamamoto; Takayoshi Yamaga; Kenichi Nishie; Chie Nagata; Rintaro Mori
Journal:  Cochrane Database Syst Rev       Date:  2019-12-04

10.  Adaptive servo ventilation for central sleep apnoea in heart failure: SERVE-HF on-treatment analysis.

Authors:  Holger Woehrle; Martin R Cowie; Christine Eulenburg; Anna Suling; Christiane Angermann; Marie-Pia d'Ortho; Erland Erdmann; Patrick Levy; Anita K Simonds; Virend K Somers; Faiez Zannad; Helmut Teschler; Karl Wegscheider
Journal:  Eur Respir J       Date:  2017-08-31       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.